Aerie Pharmaceuticals

Aerie Pharmaceuticals was an American clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates were once-daily therapies for lowering intraocular pressure with mechanisms to treat patients with glaucoma or ocular hypertension.^[1][2][3]

Aeroe Pharmaceuticals Inc.

Company type	Subsidiary
Traded as	Nasdaq: AERI
Industry	Pharmaceuticals Ophthalmology
Founded	2005; 20 years ago (2005)
Founders	David L. Epstein Casey C. Kopczynski
Defunct	August 2022 (2022-08)
Fate	Acquired
Successor	Alcon
Headquarters	Durham, North Carolina , United States
Products	Medicines that control glaucoma or ocular hypertension
Parent	Alcon
Website	aeriepharma.com

In August 2022, Swiss eye-care firm Alcon agreed to buy Aerie Pharmaceuticals for US$770 million.^[4] The acquisition completed in November 2022.^[5]